CorMedix (CRMD)
(Delayed Data from NSDQ)
$5.31 USD
+0.12 (2.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.30 -0.01 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRMD 5.31 +0.12(2.31%)
Will CRMD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRMD
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing
CRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%
Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates
Other News for CRMD
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
CorMedix announce CMA granted TDAPA to DefenCath
CVAC, SBNY and CRMD are among after hour movers
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)